Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Los participantes del ensayo clnico que tomaron tirzepatida, el medicamento vendido como Zepbound, perdieron 22,8 kilogramos (50 libras) en promedio durante 72 semanas, mientras que aquellos que tomaron semaglutida, o Wegovy, perdieron alrededor de 15 kilos (33 libras), de acuerdo con el estudio financiado por Lilly y que fue publicado en el New England Journal of Medicine
NEJM 2022 FDA Approves New Drug Treatment for Chronic Weight Management (Wegovy) FDA Approves New Medication for Chronic Weight Management (Zepbound) Frias JP et al
Vitamin B12 offers many important health benefits
While Tirzepatide is a breakthrough, it is not for everyone
That is the honest answer, and anyone telling you otherwise is oversimplifying a complicated situation
:max_bytes(150000):strip_icc()/26Q1_WL_oral-sema_newsroom_1920x1008-1dfa18327b724266bed50c36ab0b9d49.jpg)
